The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
The proteasome: a suitable antineoplastic target
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationNF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Cyclin is degraded by the ubiquitin pathway
Glotzer, M., Murray, A. W., & Kirschner, M. W. (1991) · Nature · doi:10.1038/349132a0 · Cited by 2,357
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Protein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
The ubiquitin-proteasome proteolytic pathway
Ciechanover, A. (1994) · Cell · doi:10.1016/0092-8674(94)90396-4 · Cited by 1,791
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationThe Proteasome: Paradigm of a Self-Compartmentalizing Protease
Baumeister, W., Walz, J., Zühl, F., & Seemüller, E. (1998) · Cell · doi:10.1016/s0092-8674(00)80929-0 · Cited by 1,494
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Self-citationThe ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
How Proteolysis Drives the Cell Cycle
King, R. W., Deshaies, R. J., Peters, J.-M., & Kirschner, M. W. (1996) · Science · doi:10.1126/science.274.5293.1652 · Cited by 1,273
Varfolomeev, E. E., Schuchmann, M., Luria, V., Chiannilkulchai, N., Beckmann, J. S., Mett, I. L., Rebrikov, D., Brodianski, V. M., Kemper, O. C., Kollet, O., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80609-3 · Cited by 1,234
Platelet-collagen interaction: is GPVI the central receptor?
Nieswandt, B., & Watson, S. P. (2003) · Blood · doi:10.1182/blood-2002-12-3882 · Cited by 1,150
Murray, A. W. (2004) · Cell · doi:10.1016/s0092-8674(03)01080-8 · Cited by 1,053
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 901
Glickman, M. H., Rubin, D. M., Coux, O., Wefes, I., Pfeifer, G., Cjeka, Z., Baumeister, W., Fried, V. A., & Finley, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81603-7 · Cited by 898
NF-κB as a Therapeutic Target in Multiple Myeloma
Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200360200 · Cited by 893
Self-citationRapid Destruction of Human Cdc25A in Response to DNA Damage
Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., & Lukas, J. (2000) · Science · doi:10.1126/science.288.5470.1425 · Cited by 787
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Self-citationDiehl, J. A., Zindy, F., & Sherr, C. J. (1997) · Genes & Development · doi:10.1101/gad.11.8.957 · Cited by 746
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1768 · Cited by 697
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Self-citationSherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654
In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · cited 1×
“An estimated 50% of human tumours have mutations in p53, and many other tumours are associated with alterations in the positive (ARF) or negative ( MDM2 ) regulators of p53 (Ref”
Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.9.3064 · Cited by 599
γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes
Gaczynska, M., Rock, K. L., & Goldberg, A. L. (1993) · Nature · doi:10.1038/365264a0 · Cited by 570
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Houston, M. A., Abendroth, K., Baldwin, A. S., & Liu, R. (2001) · PubMed · doi:10.17615/k359-fr77 · Cited by 547
Purification of two high molecular weight proteases from rabbit reticulocyte lysate.
Hough, R., Pratt, G., & Rechsteiner, M. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47564-3 · Cited by 545
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 538
The Proteasome, a Novel Protease Regulated by Multiple Mechanisms
DeMartino, G. N., & Slaughter, C. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22123 · Cited by 530
Structural basis for the activation of 20S proteasomes by 11S regulators
Whitby, F. G., Masters, E. I., Kramer, L., Knowlton, J. R., Yao, Y., Wang, C. C., & Hill, C. P. (2000) · Nature · doi:10.1038/35040607 · Cited by 490
Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M., & Roberts, J. M. (1996) · Genes & Development · doi:10.1101/gad.10.16.1979 · Cited by 488
Activation of the cell death program by inhibition of proteasome function
Drexler, H. C. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.855 · Cited by 481
Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N. T., Bancroft, C. C., Sausville, E. A., Adams, J., Elliott, P. J., & Waes, C. V. (2001) · PubMed · Cited by 473
Self-citationThe proteasome inhibitor PS-341 in cancer therapy.
Teicher, B. A., Ara, G., Herbst, R. S., Palombella, V. J., & Adams, J. (1999) · PubMed · Cited by 472
Self-citationp53-dependent Induction of Apoptosis by Proteasome Inhibitors
Lopes, U. G., Erhardt, P., Yao, R., & Cooper, G. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.12893 · Cited by 467
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
Self-citationA phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Aghajanian, C. A., Soignet, S. L., Dizon, D. S., Pien, C. S., Adams, J., Elliott, P. J., Sabbatini, P. J., Miller, V. A., Hensley, M. L., Pezzulli, S., et al. (2002) · PubMed · Cited by 447
Self-citationBogyo, M., McMaster, J. S., Gaczynska, M., Tortorella, D., Goldberg, A. L., & Ploegh, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6629 · Cited by 447
Ma, C. P., Slaughter, C. A., & DeMartino, G. N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50047-3 · Cited by 439
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 431
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
Bentires-Alj, M., Barbu, V., Fillet, M., Chariot, A., Relic, B., Jacobs, N., Gielen, J., Merville, M.-P., & Bours, V. (2003) · Oncogene · doi:10.1038/sj.onc.1206056 · Cited by 430
Preferential induction of apoptosis for primary human leukemic stem cells
Guzman, M. L., Swiderski, C. F., Howard, D. S., Grimes, B. A., Rossi, R. M., Szilvassy, S. J., & Jordan, C. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252462599 · Cited by 426
Ma, M. H., Yang, H. H., Parker, K., Manyak, S. J., Friedman, J. M., Altamirano, C. V., Wu, Z.-Q., Borad, M. J., Frantzen, M., Roussos, E., et al. (2003) · PubMed · Cited by 414
Self-citationUbiquitin Enters the New Millennium
Pickart, C. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00347-1 · Cited by 393
Intracellular localization of proteasomes
Wójcik, C., & DeMartino, G. N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00380-1 · Cited by 352
Read, M. A., Neish, A. S., Luscinskas, F. W., Palombella, V. J., Maniatis, T., & Collins, T. (1995) · Immunity · doi:10.1016/1074-7613(95)90030-6 · Cited by 347
Goldberg, A. L., Cascio, P., Saric, T., & Rock, K. L. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00098-6 · Cited by 345
A role for the proteasome regulator PA28α in antigen presentation
Groettrup, M., Soza, A., Eggers, M., Kuehn, L., Dick, T. P., Schild, H., Rammensee, H.-G., Koszinowski, U. H., & Kloetzel, P.-M. (1996) · Nature · doi:10.1038/381166a0 · Cited by 337
An, B., Goldfarb, R. H., Siman, R., & Dou, Q. P. (1998) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400436 · Cited by 337
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
Orlowski, M., Cardozo, C., & Michaud, C. (1993) · Biochemistry · doi:10.1021/bi00057a022 · Cited by 321
A New Ticket for Entry into Budding Vesicles—Ubiquitin
Hicke, L. (2001) · Cell · doi:10.1016/s0092-8674(01)00485-8 · Cited by 320
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Self-citationEnhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
Russo, S. M., Tepper, J. E., Baldwin, A. S., Liu, R., Adams, J., Elliott, P., & Cusack, J. C. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01446-8 · Cited by 318
Self-citationSubcellular localization of proteasomes and their regulatory complexes in mammalian cells
BROOKS, P., Fuertes, G., Murray, R. Z., Bose, S., Knecht, E., Rechsteiner, M., Hendil, K. B., Tanaka, K., Dyson, J., & Rivett, A. J. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460155 · Cited by 304
Kisselev, A. F., Akopian, T. N., Castillo, V., & Goldberg, A. L. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80341-x · Cited by 292
André, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., & Lotteau, V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13120 · Cited by 279
Dynamics of proteasome distribution in living cells
Reits, E. A. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6087 · Cited by 273
The proteasome activator 11 S REG (PA28) and Class I antigen presentation
RECHSTEINER, M., REALINI, C., & USTRELL, V. (2000) · Biochemical Journal · doi:10.1042/bj3450001 · Cited by 265
Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
Kordes, U., Krappmann, D., Heissmeyer, V, Ludwig, W., & Scheidereit, C. (2000) · Leukemia · doi:10.1038/sj.leu.2401705 · Cited by 264
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., Adams, J., & Callery, M. P. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1150 · Cited by 260
Self-citationWaxman, L., Fagan, J. M., & Goldberg, A. L. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61525-x · Cited by 259
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Chauhan, D., Li, G., Shringarpure, R., Podar, K., Ohtake, Y., Hideshima, T., & Anderson, K. C. (2003) · PubMed · Cited by 252
Regulation of apoptosis: the ubiquitous way
Yang, Y., & Xiaodan, Y. (2003) · The FASEB Journal · doi:10.1096/fj.02-0654rev · Cited by 251
Structural Features of the 26 S Proteasome Complex
Peters, J.-M., Cejka, Z., Harris, J. R., Kleinschmidt, J. A., & Baumeister, W. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1646 · Cited by 250
Proteasome Inhibition: a New Strategy in Cancer Treatment
Adams, J., Palombella, V. J., & Elliott, P. J. (2000) · Investigational New Drugs · doi:10.1023/a:1006321828515 · Cited by 248
Self-citationNefedova, Y., Landowski, T. H., & Dalton, W. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402924 · Cited by 248
Benaroudj, N., Zwickl, P., Seemüller, E., Baumeister, W., & Goldberg, A. L. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00775-x · Cited by 245
Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells
Jeremias, I., Kupatt, C., Baumann, B., Herr, I., Wirth, T., & Debatin, K. M. (1998) · Blood · doi:10.1182/blood.v91.12.4624 · Cited by 230
Down-regulation of p27 by Two Mechanisms, Ubiquitin-mediated Degradation and Proteolytic Processing
Shirane, M., Harumiya, Y., Ishida, N., Hirai, A., Miyamoto, C., Hatakeyama, S., Nakayama, K.-I., & Kitagawa, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13886 · Cited by 226
Proteasome inhibition: a new anti-inflammatory strategy
Elliott, P. J., Zollner, T. M., & Boehncke, W.-H. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0422-2 · Cited by 221
Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6194 · Cited by 212
Ling, Y. H., Liebes, L., Ng, B., Buckley, M. T., Elliott, P. J., Adams, J., Jiang, J. D., Muggia, F. M., & Perez-Soler, R. (2002) · PubMed · Cited by 205
Self-citationRole of NF-κB in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2
Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J., & Siegel, D. S. (1999) · Blood · doi:10.1182/blood.v93.9.3044 · Cited by 201
Kalejta, R. F., & Shenk, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0538058100 · Cited by 191
Kisselev, A. F., Garcia-Calvo, M., Overkleeft, H. S., Peterson, E., Pennington, M. W., Ploegh, H. L., Thornberry, N. A., & Goldberg, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303725200 · Cited by 191
Proteasome inhibition: a novel approach to cancer therapy
Adams, J. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02315-8 · Cited by 180
Self-citationRealini, C., Rogers, S. W., & Rechsteiner, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00569-9 · Cited by 172
Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol
PALMER, A., RIVETT, A. J., THOMSON, S., HENDIL, K. B., BUTCHER, G. W., FUERTES, G., & KNECHT, E. (1996) · Biochemical Journal · doi:10.1042/bj3160401 · Cited by 171
Characterization of Recombinant REGα, REGβ, and REGγ Proteasome Activators
Realini, C., Jensen, C. C., Zhang, Z.-G., Johnston, S. C., Knowlton, J. R., Hill, C. P., & Rechsteiner, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25483 · Cited by 170
Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta
Murata, S. (2001) · The EMBO Journal · doi:10.1093/emboj/20.21.5898 · Cited by 163
Ni, H., Ergin, M., Huang, Q., Qin, J., Amin, H. M., Martinez, R. L., Saeed, S., Barton, K., & Alkan, S. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03102.x · Cited by 159
Clinical update: proteasome inhibitors in solid tumors
LENZ, H. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00082-3 · Cited by 159
Eponemycin exerts its antitumor effect through the inhibition of proteasome function.
Meng, L., Kwok, B. H. B., Sin, N., & Crews, C. M. (1999) · PubMed · Cited by 155
Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells
Drexler, H. C. A., Risau, W., & Konerding, M. A. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.1.65 · Cited by 155
Chandra, J., Niemer, I., Gilbreath, J., Kliche, K. O., Andreeff, M., Freireich, E. J., Keating, M. J., & McConkey, D. J. (1998) · Blood · doi:10.1182/blood.v92.11.4220 · Cited by 147
Masdehors, P., Ōmura, S., Merle‐Béral, H., Mentz, F., Cosset, J., Dumont, J., Magdelénat, H., & Delić, J. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01388.x · Cited by 143
The Proteasome Is Involved in Angiogenesis
Oikawa, T., Sasaki, T., Nakamura, M., Shimamura, M., Tanahashi, N., Ōmura, S., & Tanaka, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8604 · Cited by 139
Involvement of Proteasomes in Regulating Jak-STAT Pathways upon Interleukin-2 Stimulation
Yu, C., & Burakoff, S. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14017 · Cited by 128
Elliott, P. J., & Ross, J. S. (2001) · American Journal of Clinical Pathology · doi:10.1309/44hw-5ycj-fllp-3r56 · Cited by 125
Amsterdam, A., Pitzer, F., & Baumeister, W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.1.99 · Cited by 120
Kim, K. B., Myung, J., Sin, N., & Crews, C. M. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00612-5 · Cited by 116
Changes in proteasome localization during the cell cycle.
Palmer, A., MASON, G. G. F., Paramio, J. M., Knecht, E., & Rivett, A. J. (1994) · PubMed · Cited by 115
Kudo, Y., Takata, T., Ogawa, I., Kaneda, T., Sato, S., Takekoshi, T., Zhao, M., Miyauchi, M., & Nikai, H. (2000) · PubMed · Cited by 108
Baldin, V., Cans, C., Knibiehler, M., & Ducommun, B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.32731 · Cited by 106
Masdehors, P., Merle‐Béral, H., Maloum, K., Ōmura, S., Magdelénat, H., & Delić, J. (2000) · Blood · doi:10.1182/blood.v96.1.269 · Cited by 98
The unfolding of substrates and ubiquitin-independentprotein degradation by proteasomes
Benaroudj, N., Tarcsa, E., Cascio, P., & Goldberg, A. L. (2001) · Biochimie · doi:10.1016/s0300-9084(01)01244-5 · Cited by 97
Characterization of the Proteasome Regulator PA28
Ahn, K., Erlander, M. G., Leturcq, D., Peterson, P. A., Früh, K., & Yang, Y. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.18237 · Cited by 96
Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin–proteasome pathway
Chen, F., Zhang, Z., Bower, J. J., Lu, Y., Leonard, S. S., Ding, M., Castranova, V., Piwnica-Worms, H. M., & Shi, X. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032428899 · Cited by 87
The 11S Regulators of 20S Proteasome Activity
Hill, C. P., Masters, E. I., & Whitby, F. G. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59414-4_4 · Cited by 78
Dietrich, C., Bartsch, T., Schanz, F., Oesch, F., & Wieser, R. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10815 · Cited by 77
Gatto, S., Scappini, B., Pham, L., Onida, F., Milella, M., Ball, G., Ricci, C., Divoký, V., Verstovšek, S., Kantarjian, H. M., et al. (2003) · PubMed · Cited by 76
The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva, I., Thomas, X., & Epstein, J. (1998) · PubMed · Cited by 75
Figueiredo‐Pereira, M. E., Chen, W. E., Li, J., & Johdo, O. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.28.16455 · Cited by 73
Bernardi, R., Liebermann, D. A., & Hoffman‐Liebermann, B. (2000) · Oncogene · doi:10.1038/sj.onc.1203564 · Cited by 71
Proteasome Inhibitors in the Treatment of B-Cell Malignancies
Schenkein, D. P. (2002) · Clinical Lymphoma · doi:10.3816/clm.2002.n.011 · Cited by 71
γ-Interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation
Bose, S., BROOKS, P., MASON, G. G. F., & Rivett, A. J. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530291 · Cited by 70
Dou, Q. P., McGuire, T. F., Peng, Y., & An, B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38201-1 · Cited by 60
Early clinical experience with the novel proteasome inhibitor PS–519
Shah, I. M., Lees, K. R., Pien, C. S., & Elliott, P. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01638.x · Cited by 51
A New Structural Class of Proteasome Inhibitors that Prevent NF-κB Activation
Lum, R. T., Kerwar, S. S., Meyer, S. M., et al. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00655-2 · Cited by 38
Inhibition of the Proteasome by Lactacystin Enhances Oligodendroglial Cell Differentiation
Pasquini, L. A., Paez, P. M., Moreno, M. A. B., Pasquini, J. M., & Soto, E. F. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-11-04635.2003 · Cited by 31
The Intracellular Localization of the Proteasome
Gordon, C. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59414-4_7 · Cited by 28
Cycling B-CLL cells are highly susceptible to inhibition of the proteasome
Bogner, C., Schneller, F., Hipp, S., Ringshausen, I., Peschel, C., & Decker, T. W. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(02)01076-7 · Cited by 27
Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors
Callus, B., & Mathey-Prevot, B. (1998) · Blood · doi:10.1182/blood.v91.9.3182 · Cited by 22
Proteasome dynamics during cell cycle in rat Schwann cells
Lafarga, M., Fernández, R., Mayo, I., Berciano, M. T., & Castaño, J. G. (2002) · Glia · doi:10.1002/glia.10075 · Cited by 21
Kip1 degradation via the ubiquitin-proteasome pathway.
Tam, S. W., Theodoras, A. M., & Pagano, M. (1997) · PubMed · Cited by 20
Wilk, S., Pereira, M. L., & Yu, B. (1991) · PubMed · Cited by 7
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states
Lecker, S. H., Goldberg, A. L., & Mitch, W. E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010083 · Cited by 1,234
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Metadata
- Authors
- Adams, J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 349-360
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2067653691
- Cited by
- 1,201
- References
- 131
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.